TCI Wealth Advisors’s Avita Medical RCEL Stock Holding History

TCI Wealth Advisors’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-322	Closed	-$4K	–	2411
2021 Q4	$4K	Buy	+322	New	+$4.91K	﹤0.01%	1879

Other funds holding RCEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

TCI Wealth Advisors's RCEL Position: Q1 2022 in Review

TCI Wealth Advisors sold out of Avita Medical (RCEL) in Q1 2022, closing a stake of 322 shares — an estimated $4K sold.

TCI Wealth Advisors first reported a position in RCEL in Q4 2021 and held it in 1 quarter. The position peaked at $4K in Q4 2021. 69 funds tracked by Wall St. Rank hold RCEL as of Q1 2022.

TCI Wealth Advisors reported no remaining Avita Medical position as of Q1 2022 after selling out during the quarter.
TCI Wealth Advisors sold 322 Avita Medical shares in Q1 2022, an estimated $4K.
TCI Wealth Advisors first reported a position in Avita Medical in Q4 2021 and held it in 1 quarter.
TCI Wealth Advisors's Avita Medical position peaked at $4K in Q4 2021.
69 funds tracked by Wall St. Rank held Avita Medical as of Q1 2022.

Based on TCI Wealth Advisors's 13F filing for Q1 2022, filed 29 Apr 2022.